Table of Contents
What is GcMAF?
Gcmaf is a vitamin D-binding protein. It’s scientifically called Gc protein-derived macrophage activating factor. It’s a protein that supports the body immune system, and naturally discovered in the body. Gcmaf activates macrophage cells, or the cells responsible for eradicating infection and disease. (1 )
The two newest publications on gcmaf aid reinterpreting the biological and medical outcomes independently observed in vitro and in vivo by a variety of scientists. The hypothesis that chondroitin sulfate might be accountable for the results so far credited to gcmaf, resolves al the disparities and contradictions that have characterized this field of immunotherapy. In addition, this hypothesis lays the structure for the advancement of non-proteinic macrophage activating aspects that are not drawn out from human blood, thus avoiding all the threats associated with human blood-derived products. (2 ).
GcMAF Research study
A 1997 study evaluated gcmaf on mice with cancer. It found that gcmaf enhanced their survival from 16 days to 32 days.
A couple of years later on, the scientists tested the treatment on people with breast, colorectal, and prostate cancers. They provided shots of a tiny amount of gcmaf as soon as a week. After a few months, all of the clients were treated, according to the research studies. Four to 7 years later, their cancers had not come back.
These outcomes sound remarkable, however there were some huge issues with the research studies. For something, they were really little– simply eight to 16 people each. Everyone in the studies had already been on standard cancer treatments like surgical treatment, chemotherapy, or radiation. So it was hard to tell whether these treatments, or gcmaf, triggered the cancers to shrink.
Likewise, doctors typically utilize imaging and lab tests to phase cancers– to put it simply, to see how huge the cancer is and whether it has actually spread out. The scientists didn’t do this. Instead, they took blood tests to check nagalase levels, which isn’t a proven way to look for cancer or to see if it has gotten smaller.
Finally, the researchers never checked whether gcmaf in fact triggered macrophages in the patients’ blood. So they couldn’t make sure that the treatment was working at all.
3 physicians from the Anticancer Fund, a not-for-profit group that promotes cancer research study, released a letter in 2014 that laid out much of the interest in the research studies. They found numerous errors in the studies’ claims and stated that its conclusions “make no sense.”.
Future of gcmaf
A couple of scientists are still examining gcmaf as a possible cancer treatment. Some early research studies recommend that it may be valuable for people with late-stage cancers. It’s tough to know whether gcmaf works. The studies that have actually been done so far took a look at extremely small numbers of individuals. A few of them consisted of only one person. Larger studies are required to prove that this treatment deals with cancer and that it’s safe.
Macrophages might still hold pledge. Scientists are attempting to learn whether monoclonal antibodies or other drugs might assist macrophages eliminate cancer cells.
Till we know more, doctors stay with other immunotherapies, like checkpoint inhibitors, that have more evidence behind them. If you have concerns about gcmaf or any other cancer treatment you have actually read about online, your cancer medical professional is the very best person to answer them. (3 ).
Illness for GcMAF Treatment
GcMAF macrophage activation therapy works in the treatment of many diseases, such as cancer, HIV AIDS, Hepatitis B virus (HBV), Hepatitis C infection (HCV), Herpes Simplex infection (HSV), Tuberculosis, Pneumonia infection, Epstein-Barr infection (EBV), cystitis/urinary tract infection (UTI), Endometriosis, Selective iga shortage condition and influenza infection.
In healthy people the immune system might have the ability to conquer lots of type of illness, however people with a jeopardized immune system will take advantage of gcmaf treatment.
In the terrific majority of people there are no side-effects with our 2nd generation GcMAF therapy, or side-effects are extremely small and exceptionally unusual. Low grade fever and eczema has actually been observed in about 1 out of 100 clients utilizing gcmaf however these were short-term effects.
Treatment in our center has been by Intramuscular (IM), Subcutaneous (SC) and Intramural (IT) injection.
In Mix With Other Treatments gcmaf can be safely used with a variety of other standard treatments and drugs to improve their effect. We describe this as integrative medicine.
A mix with anti-cancer drugs and radiation treatment (radiotherapy) is possible. For maximum result and gain from gcmaf, administer a couple of days apart from chemotherapy. Radiation therapy does not have significant results on GcMAF, so both can be utilized together at any time. In our medical experience we have observed significant cancer killing effects from gcmaf combined with palliative radiotherapy in patients who went through significant previous chemotherapy treatment.
Research studies show that gcmaf has anti-angiogenic activity in addition to tumor killing activity through the activation of macrophages.
Gcmaf can be combined with Sonodynamic Therapy (SDT), Photodynamic Therapy (PDT) or both (Sonophotodynamic Treatment, SPDT), Maitake Extract, Coley Vaccine (Coley Fluid), high-dose IV Vitamin C, low dose Naltrexone (LDN), Alpha-Lipoic Acid, hyperthermia treatment, immunotherapies and cancer vaccines (such as autologous cancer vaccine).
Gcmaf should be utilized in mix with at least 5,000 IU vitamin D3 daily. Blood levels of vitamin D are frequently low in lots of illness such as cancer, HIV AIDS, etc. Normal vitamin D levels are required for gcmaf to work totally. Have your blood 25 hydroxy-vitamin D and calcium levels tested. If blood calcium levels end up being raised, vitamin D3 doses might require to be lowered to attain an ideal balance.
Combinations to Avoid GcMAF can be securely utilized with a wide variety of drugs and other treatments. Nevertheless, we suggest:.
Minimal use of steroids is desirable because of their immune suppressing result, nevertheless steroids may be securely used with gcmaf if necessary and recommended by your doctor.
Radiation therapy is preferred over chemotherapy whenever possible.
Treatment is by intramuscular (IM) or subcutaneous (SC) injection of the gcmaf macrophage activating factor, 1-2 times per week (or as prescribed by the dealing with doctor).
Treatment in our center has actually also been by intramural (IT) injection although IM and SC injections are without a doubt the most common technique of administration.
Great aseptic handling with ethanol is required when utilizing the vials. (4 ).
How does GcMAF work?
Gcmaf is a glycoprotein that activates macrophages which in turn increases macrophage activity and changes them into Natural Killer (NK) cells.
Gcmaf has been medically demonstrated to be largely without any severe side effects. Just flu-like signs in couple of portion of those who get the injection. (5 ).
To be more particular:
In a healthy individual macrophages in our blood stream scour our bodies and kill malignancies; they get the message to go on the attack from Gc MAF, which is converted from Gc Protein. But deadly cells like cancer send an enzyme called Nagalase that stops conversion of Gc protein to Gc MAF (Macrophage Activating Element); so the macrophages never ever get the message to go into action in this way cancer reduces the body immune system, and cancer cells grow unchecked.
To reverse this we draw out Gc Protein from blood; customize it outside the body to end up being the missing GcMAF, and inject it once a week for 25 weeks for early cancers, 50 or more weeks for late stage cancers. (Encapsulated tumours need extra treatment.) HIV can require as little as 16 weeks.
In its function of immune system regulator, gcmaf reverses other diseases that attack the immune system like Osteoporosis, Aids, Hodgkins, Lupus, MS, Fibromyalgia, Parkinsons, different bacterial and viral infections and numerous types of Immune dysfunction.
Little pre-clinical trials to construct the case are again happening.
Those identified with any of these illnesses or who are otherwise encouraged of the advantages of gcmaf for their health and who have done their own research on it are welcomed to react. We request a copy of diagnostic details and upgrade reports from a doctor during and after treatments, to help construct the case that gcmaf is a treatment for numerous diseases, which will assist to make it readily available to the public. Participants are complimentary to stop at any time. (6 ).
A very relevant GcMAF history
Gcmaf first sprang to internet prestige in 2015, with an alternate health and conspiracy publication, Natural News, declaring the following.
A particular cure named gcmaf (short for “Gc protein-derived macrophage triggering element,” which is a chemically altered form of a natural protein that supposedly promotes the activity of a particular type of white blood cell) “has the possible to be a universal treatment for cancer”.
It didn’t take wish for gcmaf to achieve messianic status in the world of online hocus pocus and make-believe medical treatments. Natural News continued in the same short article;
” [gcmaf] is also believed,” the website reported, “to be efficient in treating and reversing autism, HIV, liver/kidney disease and diabetes.” Report has it that gcmaf has the potential to be a treatment for even more illness, such as herpes, as well.”.
Despite the numerous research posts released in reputable medical journals (most now pulled back) declaring to confirm gcmaf as efficient in the treatment of cancers, gcmaf does not treat cancer, or for that matter, any other condition. It was, and possibly still is, a drug for which there is no clear medical evidence to recommend efficacy for anything. Tips of promise have actually never ever equated into real results.
How it happened considered by some as the cure-all for cancer, is another tale entirely, and one well worth following. In a 2017 expose by Snopes, competently assisted by the Anticancer Fund (ACF), gcmaf was lastly exposed. In the article, its creator and main advocate, Dr. Nobuto Yamamoto. Was shown to be guilty of falsifying medical trials in a concerted decades-long effort to offer the lie of gcmaf.
The seriousness and implications of Yamamoto’s fraud have widespread ramifications for the medical neighborhood, its publications, and the processes it depends upon to confirm new medications. It has actually highlighted how a once-respected member of the medical community can go rogue, utilizing the system’s “fail-safes” against it. The gcmaf legend should not be forgotten. It works as a permanent pointer of unaddressed market loopholes, most of which remain in place.
The result of publishers not removing problematic research leads to yet more documents, based on the theories promoted in the initial disproven research study. Here is a traditional example, where 2 of Yamamoto’s documents on gcmaf have been referenced by researchers, in a recent paper entitled “Prospective role of gcmaf in suppressing the intensity of COVID-19-induced immune reactions: Lesson gained from HIV”.
2 concerns to the publications included. Why have you refused to withdraw Yamamoto’s incorrect documents and where is the peer evaluation process that would identify the research in the paper referenced above to be flawed? Permitting incorrect and flawed studies to continue endangers the public.
You can discover the complete Snopes Short article here. Entitled, “How a Retired Scientist’s Questionable ‘Institute’ Convinced the Internet That Cancer Was Treated”, it produces fascinating reading and we recommend it as a case study in professionally perpetrated pharmaceutical deceptiveness. Yamamoto had actually taken pleasure in a long and prominent profession till gcmaf, making the motivation for the fraud that much harder to determine, and professionals remain divided on his true inspiration.
In November of 2009, Yamamoto effectively sold his patents for gcmaf and associated intellectual property to an Israeli biopharmaceutical company, Efranat Macrophage. The company, after at first embracing Yamamoto, gradually distanced itself from him, rebranding gcmaf as EFF-022 and reaching changing the drug’s name mid-trial.
While the medical neighborhood gradually turned their backs on gcmaf, the alternate health and conspiracy sections of the web were far from done with their brand-new darling, having actually seen the marketing and sales capacity for this brand-new “miracle” treatment. (7 )
“Cancer cured for good?”– GcMAF and the miracle cure
As an organisation committed to beating cancer, we have a deep-rooted interest in any new research study advancements that might cause new, more efficient treatments for the disease.
So when we received a query from an advocate about an article entitled “Cancer treated for good” by Bill Sardi and Timothy Hubbell * we were captivated. The article discuss research by Nobuto Yamamoto in the United States, taking a look at a protein called GcMAF (aka gcmaf). His published research studies appear to show that injections of really small amounts of GcMAF can “cure” individuals with breast, bowel and prostate cancer.
According to the article, “It works 100% of the time to remove cancer entirely, and cancer does not repeat even years later.” Could this be the so-called ‘remedy for cancer’ that we’ve been searching for all these years?
Unfortunately– similar to many things in life– if it sounds too great to be true it probably is. Major concerns are now being raised about GcMAF (for instance, this examination by the BBC) and the business that sell it, and it is not certified in the UK to deal with any disease.
Let’s explore a bit further.
What’s the idea behind it?
Dr Yamamoto studies the immune system– the highly complex network of cells that assists to keep us healthy. The cells of the immune system– white blood cells– battle bacterial and viral infections since they can identify and attack these ‘foreign’ invaders. However they’re not so proficient at taking on cancer, because tumours grow from our own cells and have clever mechanisms to ‘cloak’ them from immune attack.
Macrophages (meaning “huge eaters” in Greek) are an important kind of white blood cell. They patrol the body, eating up foreign intruders and dead cells. They also help to alert other immune cells to the existence of infections.
Macrophages can be stirred into action by a little sugar-coated protein (glycoprotein) called GcMAF, short for Gc Macrophage Triggering Factor, which is produced by the body. But it’s believed that the production of GcMAF is obstructed by an enzyme called Nagalase (alpha-N-acetylgalactosaminidase), produced by numerous cancers. This is one of the mechanisms that helps tumours avert the body immune system.
Yamamoto’s theory is that injecting cancer patients with GcMAF need to trigger their macrophages to combat the cancer. He checked it back in 1997 in a paper published in the journal Cancer Research study, revealing that injecting GcMAF into mice transplanted with cancer cells might improve their survival from around 16 days to around 35.
However the treatment did not ‘treat’ the cancer, as the cancer cells continued to multiply, ultimately eliminating the animals.
Nevertheless, there are questions about the science underpinning the idea that GcMAF can treat cancer. For instance, other researchers have actually discovered no distinctions in the levels of GcMAF between cancer clients and healthy people– and the levels they do find are far higher than the very small dosages proposed to work by Yamamoto. It’s hard to see precisely how this finding fits with the concept of how the treatment is supposed to work, and it does not support the use of GcMAF as a treatment for cancer.
Fast-forward a couple of years, to the publication of 3 documents detailing the outcomes of medical trials of GcMAF performed by Yamamoto, testing the treatment on clients with breast, bowel and prostate cancer.
Note: The breast cancer paper has now been retracted, due to various interest in the work. Read more on the retractionwatch blog. The bowel cancer paper has also now been withdrawed. This letter details a few of the concerns about the work.
The outcomes appear to be startling– all the patients on the trials are ‘treated’ of cancer. Surely this is an incredible breakthrough?
Put candidly, no it isn’t. There are significant scientific issues with the trials. For a start, all the studies are extremely little, involving less than twenty patients in each– rather than the thousands needed to make the sort of claims discussed above.
Next, all the patients included had gotten basic treatment for their cancer, including surgical treatment, chemotherapy and/or radiotherapy. This is a rather unorthodox design for a trial of this kind, since it makes it extremely challenging to tell if any successes are because of the brand-new drug, or the more standard treatments.
On top of this, the scientists didn’t really monitor the progress of tumours in the clients, and supply no clinical details about them. Rather they decide to measure levels of Nagalase in the blood, rather than looking at any basic established markers for cancer.
For example, when it comes to the breast cancer patients, there is no information about their “TNM” (tumour, node, metastasis) status. This is a basic measure of how far a patient’s cancer has spread, and is used to determine the possibility that it will return.
Furthermore, the researchers didn’t do any tests to reveal that injected GcMAF was really activating macrophages in the clients’ blood, or even working in the way that they anticipate. There is no details about levels of cytokines– the proteins produced by immune cells when they are triggered– or analysis of the patients’ immune cells.
Possibly most significantly, there are no controls– without treatment patients for comparison– and the research studies just followed the patients for a couple of years. We have no way of telling whether their cancers were growing again, or had actually been successfully treated, and whether this was due to GcMAF or the other treatment they had received.
Given that 80 percent of all ladies with breast cancer make it through for at least 5 years, an uncontrolled research study showing that 16 women of unknown TNM status survive for at least 4 years is no terrific shakes, clinically speaking.
Another little study of 20 clients with a variety of cancers, published in 2013, has comparable problems. It’s not a regulated trial, and the scientists only measure nagalase levels as an indication of whether the treatment is ‘working’, and offer really little hard scientific data (such as scans or other acknowledged tests) about the patients’ real tumours. For example, in one worrying case, although the scientists revealed that an ovarian cancer patient’s nagalase levels had actually decreased, the levels of another marker– CA125, which is produced by ovarian cancer cells– had actually increased. Yet this is classed as an “enhancement” in the paper, without any other supporting information. In general, this study is likewise a long way from being persuading evidence that the treatment works.
Another informing point is the kind of journal in which the research study was published. If this research was really innovative, and pointed the way to a remedy for cancer, then the research would likely be discovered in top-tier ‘high-impact’ medical journals like The Lancet, The New England Journal of Medicine or the Journal of the American Medical Association.
And lastly, essentially all the referrals in the documents are to other papers published by Yamamoto and his group. If GcMAF was certainly an appealing prospect for a successful cancer treatment, you ‘d anticipate a lot of other research study to reveal the very same thing. Researchers are typically fast to find promising, emerging fields of research study and follow suit.
The poor quality of scientific documents supporting gcmaf is discussed here on the Scholarly Open Gain access to blog.
Is there hope?
Although this particular method isn’t all it’s hyped approximately be, harnessing the power of immune system could be an extremely powerful way to treat cancer.
And numerous Cancer Research study UK-funded scientists are also operating in this field. For example, Teacher Fran Balkwill and her team are dealing with ways to fool macrophages and other immune cells into attacking cancer cells.
In 2014, scientists in Israel started a small early-stage scientific trial taking a look at the dose and safety of gcmaf in cancer clients. (8 ).
Dr Yamamoto specifies gcmaf does not have negative effects. Our experiences agree: gcmaf has actually revealed no negative effects of its own. That’s not unexpected– your body anticipates to have it.
However your rebuilt immune system may in some cases give you minor adverse effects, but larger negative effects with late stages of cancer, and sometimes extreme impacts with autism, HIV and ME/CFS, as infections fight back against the reconstructed immune system’s attack.
Individuals’s reactions to a reconstructed immune system are extremely various– from zero, which is normal, to extreme in a minority of cases.
Inside 2 hours gcmaf will start to affect your immune system, and (if your body immune system is at least partially active) a shot of 0.1 ml or more may cause fatigue which typically lasts 3-4 hours. You might feel better than typical for the very first 2-3 weeks as the body immune system gets up.
Gcmaf is a protein that your body ought to have made by itself, and there is a tiny possibility (under 0.1%) you might have an allergic reaction, usually within the first 2 hours. If in doubt start with a 0.05 ml dose, then 0.1 after 12 hours. If you do have a response, it can be treated with anti-histamine tablets, which can normally be bought from a chemist without prescription (hay fever is an allergic reaction).
We have actually seen positive, but not yet negative autoimmune responses.
Other minor adverse effects may consist of cytokine activity (with accompanying fatigue and minor weight loss, no such reports yet), histamine release (with possibly a headache) and the signs of a fever (3.5 hours of hot flushes) as the immune system goes to work.
Most never notice anything more than an enhancing sense of well being. (9 ).
Other essential points
Activating macrophages with High Dose GcMAF is a vital part of any treatment program which can be used alone or in combination with many other therapies.
GcMAF works particularly well in synergy with targeted therapies which do not hurt the immune system. Examples of targeted treatments consist of hormone treatments, monoclonal antibody drugs, small-molecule drugs, signal transduction inhibitors (HER2 inhibitors, BRAF inhibitors, EGFR inhibitors), angiogenesis inhibitors, immunotherapy drugs (such as drugs that target CTLA-4 protein).
2nd Generation GcMAF has the advantage of having no adverse effects so treatment should be continued as long as necessary while illness exists. This is a significant benefit over lots of conventional treatments which have cumulative toxicity that limits their use.
GcMAF never quits working and will continue to activate macrophages while treatment is continued, either by GcMAF injections and/or oral administration of Colostrum GcMAF. (10 ).